Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH – Get Rating) have been assigned a consensus rating of “Hold” from the ten brokerages that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $10.19.
A number of equities research analysts have issued reports on TBPH shares. StockNews.com initiated coverage on shares of Theravance Biopharma in a report on Thursday, March 31st. They set a “hold” rating for the company. Morgan Stanley raised their target price on shares of Theravance Biopharma from $10.00 to $11.00 and gave the company an “underweight” rating in a research note on Wednesday, March 2nd. Finally, HC Wainwright boosted their price target on shares of Theravance Biopharma from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, February 24th.
TBPH stock opened at $9.10 on Tuesday. Theravance Biopharma has a 1-year low of $6.10 and a 1-year high of $19.98. The stock has a market capitalization of $690.71 million, a PE ratio of -4.44 and a beta of 0.78. The business has a fifty day simple moving average of $9.75.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Rhumbline Advisers lifted its holdings in shares of Theravance Biopharma by 2.8% in the 4th quarter. Rhumbline Advisers now owns 62,531 shares of the biopharmaceutical company’s stock valued at $691,000 after acquiring an additional 1,682 shares during the last quarter. California State Teachers Retirement System lifted its stake in shares of Theravance Biopharma by 2.7% in the 3rd quarter. California State Teachers Retirement System now owns 75,440 shares of the biopharmaceutical company’s stock valued at $558,000 after purchasing an additional 1,983 shares during the last quarter. Swiss National Bank boosted its holdings in shares of Theravance Biopharma by 1.9% in the 4th quarter. Swiss National Bank now owns 121,342 shares of the biopharmaceutical company’s stock worth $1,341,000 after purchasing an additional 2,300 shares during the period. Arizona State Retirement System increased its position in shares of Theravance Biopharma by 20.8% during the 3rd quarter. Arizona State Retirement System now owns 14,705 shares of the biopharmaceutical company’s stock valued at $109,000 after purchasing an additional 2,531 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Theravance Biopharma by 49.5% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,548 shares of the biopharmaceutical company’s stock valued at $82,000 after buying an additional 2,830 shares during the period. Hedge funds and other institutional investors own 78.14% of the company’s stock.
Theravance Biopharma Company Profile (Get Rating)
Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.
- Get a free copy of the StockNews.com research report on Theravance Biopharma (TBPH)
- Shopify (NYSE: SHOP) Approaches Key Support Level
- Follow The Money To Cigna
- Intuitive Surgical is an Intuitive Buy
- The Low In Lordstown Motors May Not Be The Last
- MarketBeat Podcast: Barbell Strategy To Strengthen Your Portfolio
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.